Daniel S. Levine

Daniel S. Levine is editor of Rare Daily. You can contact him by sending email to editor@globalgenes.org

Are Orphan Drugs Losing their Luster?
The orphan drug market is experiencing strong growth, but there are signs that pricing pressures may be impacting the sector, raising… Continue Reading
Centogene Enters Agreement with Aldeyra Therapeutics Focused on Sjögren-Larsson Syndrome
Rare Daily Staff Centogene said it has entered into a collaboration with Aldeyra Therapeutics to globally identify patients with… Continue Reading
FDA Accepts for Priority Review Catalyst Pharmaceuticals’ Application to Market Firdapse for LEMS
Rare Daily Staff The U.S. Food and Drug Administration accepted Catalyst Pharmaceuticals’ application to market its Firdapse for the rare… Continue Reading
FDA Approves BioMarin’s Enzyme Therapy for PKU
Rare Daily Staff The U.S. Food and Drug Administration approved BioMarin Pharmaceutical’s Palynziq for adult patients with phenylketonuria… Continue Reading
An Ironman Champion with Cystic Fibrosis Discusses her Changing Relationship with Her Disease
Lisa Bentley spent 20 years competing as a professional athlete, although early in her career she kept secret that she suffered from the… Continue Reading
FDA Grants Breakthrough Therapy Designation to Bluebird Bio’s Gene Therapy for CALD
Rare Daily Staff The U.S. Food and Drug Administration granted Breakthrough Therapy designation to Bluebird Bio’s ALD-102, its… Continue Reading
Study Finds Facial Analysis Software Able to Identify Patients with Williams-Beuren Syndrome
Rare Daily Staff A new study has shown that researchers have successfully used facial analysis technology and clinical information to… Continue Reading
be-a-guest-blogger

Follow us on Twitter